Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nexstim OyjFRA:5NX +6.07%69 EV-to-EBIT is 134.94 as of Sep. 07, 2026. GuruFocus rates FRA:5NX with a GF Score™ of 69/100 and a GF Value™ of €9.65 (Fairly Valued). The stock has 5 warning signs investors should review. Among 475 Medical Devices & Instruments companies, Nexstim Oyj ranks worse than 94.74% on this metric.
The historical rank and industry rank for Nexstim Oyj's EV-to-EBIT or its related term are showing as below:
FRA:5NX'
s EV-to-EBIT Range Over the Past 10 Years
Min: -269.05 Med: -0.36 Max: 134.94
Current: 134.94
During the past 13 years, the highest EV-to-EBIT of Nexstim Oyj was 134.94. The lowest was -269.05. And the median was -0.36.
FRA:5NX's EV-to-EBIT is ranked worse than 94.74% of 475
companies
in the Medical Devices & Instruments industry
Industry Median: 18.52
vs FRA:5NX: 134.94
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Nexstim Oyj's Enterprise Value for the quarter that ended in Jun. 2026 was €69.24 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nexstim Oyj's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €0.56 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nexstim Oyj EV-to-EBIT Related Terms
Nexstim Oyj EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Nexstim Oyj's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Nexstim Oyj's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nexstim Oyj EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nexstim Oyj's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Nexstim Oyj's EV-to-EBIT falls into.
Nexstim Oyj's current Enterprise Value is €75.97 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nexstim Oyj's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €0.56 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nexstim Oyj (FRA:5NX) has a EV-to-EBIT of 134.94 as of Sep. 07, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Nexstim Oyj and its competitors. According to the industry distribution chart, Nexstim Oyj ranks #450 out of 475 companies in the Medical Devices & Instruments industry, placing it in the top 94.7%.
Is Nexstim Oyj's EV-to-EBIT too high?
Nexstim Oyj's current EV-to-EBIT is 134.94. The Medical Devices & Instruments industry median EV-to-EBIT is 18.52. Nexstim Oyj's value of 134.94 is 628.6% above this industry median. Based on the distribution chart, Nexstim Oyj ranks #450 out of 475 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Nexstim Oyj has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Nexstim Oyj's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nexstim Oyj ranks #450 out of 475 companies for EV-to-EBIT. This places Nexstim Oyj in the lower half of its industry. The industry median EV-to-EBIT is 18.52. Nexstim Oyj's value of 134.94 is 628.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.52, based on 475 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nexstim Oyj's current EV-to-EBIT of 134.94 is 628.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Nexstim Oyj and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nexstim Oyj's current EV-to-EBIT is 134.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nexstim Oyj stock overvalued right now?
Based on GuruFocus' analysis, Nexstim Oyj (FRA:5NX) is currently considered Fairly Valued. The stock's GF Value™ is €9.65, compared to a current price of €9.78 — trading 1.3% above its estimated fair value. The current EV-to-EBIT is 134.94 and 628.6% above the Medical Devices & Instruments industry median of 18.52. Nexstim Oyj's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Nexstim Oyj (FRA:5NX), the current EV-to-EBIT is 134.94 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nexstim Oyj (FRA:5NX) Overvalued in 2026?
Based on GuruFocus' analysis, Nexstim Oyj stock appears to be overvalued.
The current stock price of €9.78 is trading 1.3% above its estimated GF Value™ of €9.65.
GuruFocus considers Nexstim Oyj to be Fairly Valued.
Key valuation signals for FRA:5NX:
EV-to-EBIT: 134.94
GF Value™: €9.65 vs. price of €9.78 (1.3% above fair value)
Industry Position: 628.6% above the Medical Devices & Instruments median (#450 of 475)
No single metric tells the full story. See the FRA:5NX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nexstim Oyj is a Finnish medical technology company. It has developed a non-invasive brain-stimulation technology for navigated transcranial magnetic stimulation (nTMS), with sophisticated 3D navigation that provides accurate, personalized targeting of TMS to specific brain areas. The company's diagnostic business focuses on commercializing the NBS System 6, an FDA-cleared, CE-marked navigated TMS system for pre-surgical mapping of the brain's speech and motor cortices. Its therapy business sells the NBS System 6 for the treatment of depressive disorder in the United States, and for the treatment of depression, chronic neuropathic pain, and post-operative rehabilitation of motor deficits of the upper limb, in Europe. Geographically, the firm generates maximum revenue from North America.
69GF Score
Get the complete analysis for FRA:5NX
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5NX has been successfully added to your 
